debt_leverage_profile
Minimal debt; early-stage medical device company largely equity-financed. A 20% rate rise has negligible direct debt-service impact.
Inferred
Agent_Inference
interest_rate_sensitivity
Low sensitivity to rate changes on debt; higher rates increase cost of future equity dilution rounds and extend cash runway pressure.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Semiconductor/MEMS fabrication concentrated in Taiwan/South Korea; specialty biocompatible polymer sourcing from limited EU suppliers.
Inferred
Agent_Inference
international_expansion_readiness
Predominantly US-revenue; minimal international sales exposure. Sovereign currency devaluation risk is near-zero at current stage.
Inferred
Agent_Inference
geographic_footprint
Essentially 100% US-focused revenue; no material international market presence yet, so currency devaluation exposure is negligible.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single CMOS/silicon foundry partners for thin-film electrode fabrication; substitution would require 12-24 month requalification.
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure termination would cause moderate disruption to data management/R&D workflows but not core device manufacturing or regulatory filings.
Inferred
Agent_Inference
business_model_type_secondary
Hardware medical device manufacturer with IP licensing aspirations; cloud dependency is secondary to physical manufacturing and FDA regulatory pathway.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company is hardware-centric. Software/cloud API dependencies are internal R&D tools, not customer-facing integrations.
Inferred
Agent_Inference
howey_test_risk_index
Revenue from device sales/licensing does not constitute an investment contract; Howey Test risk is not applicable to this business model.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Minimal GDPR/CCPA exposure currently; as neural data collection scales, patient neural data will trigger significant HIPAA and emerging neurorights regulations.
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche early-stage market with no dominant share. Competitive landscape includes Medtronic and Blackrock Neurotech as larger incumbents.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional/milestone-based; revenue from device sales, R&D partnerships, and grants. Recurring revenue near 0% at current commercialization stage.
Inferred
Agent_Inference
monetization_vector
Primary monetization via capital equipment device sales to neuroscience researchers and hospitals, supplemented by government/NIH grant funding.
Inferred
Agent_Inference
pricing_architecture
Premium pricing tied to superior electrode density and biocompatibility; pricing power dependent on FDA clearance milestones and clinical validation data.
Inferred
Agent_Inference
pricing_power_rating
Moderate-to-high pricing power if clinical differentiation proven; risk of compression if larger incumbents replicate thin-film technology at scale.
Inferred
Agent_Inference
target_gross_margin_bracket
56.5% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
No meaningful free-rider leakage; hardware product with regulated procurement. Research institutions require formal purchase agreements.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is largely headcount-sublinear at scale; manufacturing automation and IP licensing can decouple revenue from linear headcount addition.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth currently high due to custom fabrication; scales favorably if volume manufacturing partnerships established with foundries.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; NeuroOne does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely compresses as clinical evidence accumulates; but hospital procurement cycles remain long, capping rapid unit economics improvement.
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect effects possible if neural data ecosystem or clinical trial partnerships create switching costs and data moats.
Inferred
Agent_Inference
asset_efficiency_ratio
-33.4% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Low recession resistance; capital equipment for neuroscience research is discretionary institutional spending, vulnerable to NIH budget cuts and hospital capex freezes.
Inferred
Agent_Inference
customer_segment_primary
Academic and government-funded neuroscience research institutions (NIH-backed labs); high concentration risk as few large customers dominate early revenue.
Inferred
Agent_Inference
customer_segment_secondary
Specialty neurology hospital centers and epilepsy surgery programs evaluating next-generation electrode arrays for clinical diagnostic use.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.9% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001500198
High
SEC-EDGAR
ticker
NMTC
High
SEC-EDGAR